肝细胞癌微血管侵犯的预测及治疗进展

何涛; 蒋禹; 李秋; 付文广

doi:10.3969/j.issn.1001-5256.2020.05.053

肝细胞癌微血管侵犯的预测及治疗进展

DOI: 10.3969/j.issn.1001-5256.2020.05.053

1. 西南医科大学附属医院肝胆外科
2. 西南医科大学附属医院四川省院士(专家)工作站

基金项目:

四川省科技计划项目基金资助（2018JY0283;2017SZYZF0015）；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1109
- HTML全文浏览量: 34
- PDF下载量: 139
- 被引次数: 0
出版历程
- 出版日期: 2020-05-20

Research advances in microvascular invasion in hepatocellular carcinoma

Department of Hepatobiliary Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China

Research funding:

摘要

摘要:
尽管目前肝细胞癌(HCC)采用联合多学科、多种方式的综合治疗,但仍有很大部分患者预后较差。现有研究表明微血管侵犯(MVI)是HCC发生不良预后的重要因素之一,但目前MVI只能通过术后病理证实。分析总结了近年来有关于MVI发生的相关因素及治疗措施,以更深入的了解MVI的研究进展。
- 癌,肝细胞 /
- 肿瘤侵润 /
- 微血管 /
- 危险因素
Abstract:
Although hepatocellular carcinoma(HCC) is treated with a combination of multiple disciplines and methods, there are still a large number of patients with poor prognosis. Current studies have shown that microvascular invasion(MVI) is one of the important factors for poor prognosis of HCC, but MVI can only be confirmed by postoperative pathology. This article analyzes and summarizes the factors and treatment measures for MVI in recent years, so as to better understand the research advances in MVI.
- carcinoma,hepatocellular /
- neoplasm invasiveness /
- microvessels /
- risk factors

HTML全文

参考文献(55)

[1] ZHOU J, SUN HC, WANG Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China(2017 Edition)[J]. Liver Cancer, 2018, 7(3):235-260.

[2] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis, management, and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017, 33(8):1419-1431.(in Chinese）中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范（2017年版）[J]．临床肝胆病杂志，2017, 33(8):1419-1431.

[3] WANG H, FENG LH, QIAN YW, et al. Does microvascular invasion in Barcelona Clinic Liver Cancer stage A multinodular hepatocellular carcinoma indicate early-stage behavior?[J]. Ann Transl Med, 2019, 7(18):428.

[4] HUANG Y, ZHANG Z, ZHOU Y, et al. Should we apply sorafenib in hepatocellular carcinoma patients with microvascular invasion after curative hepatectomy?[J]. Onco Targets Ther,2019, 12:541-548.

[5] WANG H, WU MC, CONG WM. Microvascular invasion predicts a poor prognosis of solitary hepatocellular carcinoma up to 2 cm based on propensity score matching analysis[J].Hepatol Res, 2019, 49(3):344-354.

[6] CHEN ZH, ZHANG XP, WANG H, et al. Effect of microvascular invasion on the postoperative long-term prognosis of solitary small HCC:A systematic review and meta-analysis[J].HPB(Oxford), 2019, 21(8):935-944.

[7] HIROKAWA F, HAYASHI M, ASAKUMA M, et al. Risk factors and patterns of early recurrence after curative hepatectomy for hepatocellular carcinoma[J]. Surg Oncol, 2016, 25(1):24-29.

[8] YEN YH, CHANGCHIEN CS, WANG JH, et al. A modified TNMbased Japan Integrated Score combined with AFP level may serve as a better staging system for early-stage predominant hepatocellular carcinoma patients[J]. Dig Liver Dis, 2009, 41(6):431-441.

[9] JIN J, NIU X, ZOU L, et al. AFP mRNA level in enriched circulating tumor cells from hepatocellular carcinoma patient blood samples is a pivotal predictive marker for metastasis[J]. Cancer Lett, 2016, 378(1):33-37.

[10] WANG H, QIAN YW, WU MC, et al. Liver resection is justified in patients with BCLC Intermediate stage hepatocellular carcinoma without microvascular invasion[J]. J Gastrointest Surg,2019, 25(1):128-135.

[11] RYU T, TAKAMI Y, WADA Y, et al. A clinical scoring system for predicting microvascular invasion in patients with hepatocellular carcinoma within the Milan Criteria[J]. J Gastrointest Surg, 2019, 23(4):779-787.

[12] FUJIKAWA T, SHIRAHA H, UEDA N, et al. Des-gammacarboxyl prothrombin-promoted vascular endothelial cell proliferation and migration[J]. J Biol Chem, 2007, 282(12):8741-8748.

[13] YAMASHITA YI, IMAI K, YUSA T, et al. Microvascular invasion of single small hepatocellular carcinoma≤3 cm:Predictors and optimal treatments[J]. Ann Gastroenterol Surg,2018, 2(3):197-203.

[14] POTÉN, CAUCHY F, ALBUQUERQUE M, et al. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion[J]. J Hepatol, 2015, 62(4):848-854.

[15] SULLIVAN KM, GROESCHL RT, TURAGA KK, et al. Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma:A Western perspective[J]. J Surg Oncol, 2014, 109(2):95-97.

[16] GUO Y, CUI W, PEI Y, et al. Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-βsignaling pathway[J]. Gynecol Oncol, 2019,153(3):639-650.

[17] LIN X, LI W, LAI J, et al. Five-year update on the mouse model of orthotopic lung transplantation:Scientific uses, tricks of the trade, and tips for success[J]. J Thorac Dis, 2012, 4(3):247-258.

[18] FU SJ, SHEN SL, LI SQ, et al. Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy[J]. Med Oncol, 2013, 30(4):721.

[19] RUNGSAKULKIJ N, MINGPHRUEDHI S, SURAGUL W, et al.Platelet-to-lymphocyte ratio and large tumor size predict microvascular invasion after resection for hepatocellular carcinoma[J]. Asian Pac J Cancer Prev, 2018, 19(12):3435-3441.

[20] YU Y, SONG J, ZHANG R, et al. Preoperative neutrophil-tolymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocel ular carcinoma[J]. Oncotarget, 2017, 8(45):79722-79730.

[21] DENG G, YAO L, ZENG F, et al. Nomogram for preoperative prediction of microvascular invasion risk in hepatocellular carcinoma[J]. Cancer Manag Res, 2019, 11(1):9037-9045.

[22] LI P, HUANG W, WANG F, et al. Nomograms based on inflammatory biomarkers for predicting tumor grade and microvascular invasion in stage I/II hepatocellular carcinoma[J].Biosci Rep, 2018, 38(6):BSR20180464.

[23] WANG X, MA C, ZONG Z, et al. A20 inhibits the motility of HCC cells induced by TNF-α[J]. Oncotarget, 2016, 7(12):14742-14754.

[24] FU XT, DAI Z, SONG K, et al. Macrophage-secreted IL-8induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway[J]. Int J Oncol, 2015, 46(2):587-596.

[25] LI Z, LEI Z, XIA Y, et al. Association of preoperative antiviral treatment with incidences of microvascular invasion and early tumor recurrence in hepatitis B virus-related hepatocellular carcinoma[J]. JAMA Surg, 2018, 153(10):e182721.

[26] QU C, HUANG X, LIU K, et al. Effect of hepatitis B virus DNA replication level and anti-HBV therapy on microvascular invasion of hepatocellular carcinoma[J]. Infect Agent Cancer,2019, 14:2.

[27] HE J, SHI J, FU X, et al. The clinicopathologic and prognostic significance of gross classification on solitary hepatocellular carcinoma after hepatectomy[J]. Medicine(Baltimore),2015, 94(32):e1331.

[28] KIM BK, HAN KH, PARK YN, et al. Prediction of microvascular invasion before curative resection of hepatocellular carcinoma[J]. J Surg Oncol, 2008, 97(3):246-252.

[29] BELLA L, ZONA S, NESTAL DE MORAES G, et al. FOXM1:A key oncofoetal transcription factor in health and disease[J].Semin Cancer Biol, 2014, 29:32-39.

[30] WANG X, JUNG YS, JUN S, et al. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness[J]. Nat Commun, 2016, 7:10633.

[31] ZHANG T, GUO J, GU J, et al. KIAA0101 is a novel transcriptional target of FoxM1 and is involved in the regulation of hepatocellular carcinoma microvascular invasion by regulating epithelial-mesenchymal transition[J]. J Cancer, 2019, 10(15):3501-3516.

[32] LAMOUILLE S, XU J, DERYNCK R. Molecular mechanisms of epithelial-mesenchymal transition[J]. Nat Rev Mol Cell Bio,2014, 15(3):178-196.

[33] YU SL, WU JC, LIU PF, et al. Up-regulation of RNF187 induces hepatocellular carcinoma cell epithelial to mesenchymal transitions[J]. Oncotarget, 2017, 8(60):101876-101886.

[34] SUN L, LI PB, YAO YF, et al. Proteinase-activated receptor2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma[J]. World J Gastroenterol,2018, 24(10):1120-1133.

[35] CAI L, YE Y, JIANG Q, et al. Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma[J]. Nat Commun, 2015, 6:7353.

[36] YU YQ, JIN Y, ZHOU JL, et al. Sero-biomarkers for predicting microvascular invasion in hepatocellular carcinoma before liver resection[J]. HPB, 2016, 18:e198.

[37] ENOOKU K, URANBILEG B, IKEDA H, et al. Higher LPA2 and LPA6 mRNA levels in hepatocellular carcinoma are associated with poorer differentiation, microvascular invasion and earlier recurrence with higher serum autotaxin levels[J]. PLoS One,2016, 11(9):e0161825.

[38] ARSENII N, PIARDI T, DIÉBOLD MD, et al. Impact of visceral obesity on microvascular invasion in hepatocellular carcinoma[J]. Cancer Invest, 2016, 34(6):1-8.

[39] HUANG M, LIAO B, XU P, et al. Prediction of microvascular invasion in hepatocel ular carcinoma:Preoperative Gd-EOB-DTPA-dynamic enhanced MRI and histopathological correlation[J]. Contrast Media Mol Imaging, 2018, 2018:9674565.

[40] KOBAYASHI T, AIKATA H, HONDA F, et al. Preoperative Fluorine 18 Fluorodeoxyglucose positron emission tomography/computed tomography for prediction of microvascular invasion in small hepatocellular carcinoma[J]. J Comput Assist Tomogr, 2016, 40(4):524-530.

[41] WU TH, HATANO E, YAMANAKA K, et al. A non-smooth tumor margin on preoperative imaging predicts microvascular invasion of hepatocellular carcinoma[J]. Surg Today, 2016,46(11):1275-1281.

[42] HE T, GUO XD, YU K, et al. Preliminary study on the value of des-γ-carboxy-prothrombin combined with enhanced CT in predicting microvascular invasion of hepatocellular carcinoma[J]. Chin J Pract Surg, 2019, 39(10):1065-1067.(in Chinese）何涛，郭晓冬，余快，等．异常凝血酶原联合增强CT预测肝癌微血管侵犯价值研究[J]．中国实用外科杂志，2019, 39(10):1065-1067.

[43] ZHENG J, CHAKRABORTY J, CHAPMAN WC, et al. Preoperative prediction of microvascular invasion in hepatocellular carcinoma using quantitative image analysis[J]. J Am Coll Surg,2017, 225(6):778-788.

[44] WANG LL, LI JF, DOU Y, et al. Value of magnetic resonance functional imaging in evaluating microvascular invasion of hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34(12):2681-2684.(in Chinese）王莉莉，李俊峰，窦郁，等．MR功能成像对肝细胞癌微血管侵犯的评估价值[J]．临床肝胆病杂志，2018, 34(12):2681-2684.

[45] ZHAO J, LI X, ZHANG K, et al. Prediction of microvascular invasion of hepatocellular carcinoma with preoperative diffusionweighted imaging:A comparison of mean and minimum apparent diffusion coefficient values[J]. Medicine(Baltimore), 2017, 96(33):e7754.

[46] WANG WT, YANG L, YANG ZX, et al. Assessment of microvascular invasion of hepatocellular carcinoma with diffusion kurtosis imaging[J]. Radiology, 2018, 286(2):571-580.

[47] WANG YT, ZUO CJ, ZHANG J, et al. Value of Fluorine-18-fluorodeoxyglucose PET/CT examination to predict microvascular invasion of hepatocellular carcinoma[J]. Chin J Dig Surg, 2018,17(1):109-115.(in Chinese）王玉涛，左长京，张建，等．18氟-氟代脱氧葡萄糖PET/CT检查预测肝细胞癌微血管侵犯的价值[J]．中华消化外科杂志，2018, 17(1):109-115.

[48] UENO S, KUBO F, SAKODA M, et al. Efficacy of anatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification[J]. J Hepatobiliary Pancreat Surg, 2008, 15(5):493-500.

[49] YANG P, SI A, YANG J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]. Surgery, 2019, 165(4):721-730.

[50] KISHI Y, HASEGAWA K, KOKUDO N. Surgical resection for small hepatocellular carcinoma in cirrhosis:The Eastern experience[J]. Recent Results Cancer Res, 2013, 190:69-84.

[51] SHI C, ZHAO Q, LIAO B, et al. Anatomic resection and wide resection margin play an important role in hepatectomy for hepatocellular carcinoma with peritumoural micrometastasis[J]. ANZ J Surg, 2019, 89(11):e482-e486.

[52] TAN Y, ZHANG W, JIANG L, et al. Efficacy and safety of anatomic resection versus nonanatomic resection in patients with hepatocellular carcinoma:A systemic review and meta-analysis[J]. PLoS One, 2017, 12(10):e0186930.

[53] YE JZ, CHEN JZ, LI ZH, et al. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion[J]. World J Gastroenterol, 2017, 23(41):7415-7424.

[54] SUN JJ, WANG K, ZHANG CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after r0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion[J]. Ann Surg Oncol, 2016,23(4):1344-1351.

[55] ZHANG XJ, WANG L. Clinical significance of microvascular invasion in the comprehensive diagnosis and treatment of hepatocellular carcinoma[J]. Chin J Dig Surg, 2019, 18(4):336-341.(in Chinese）张小晶，王琳．微血管侵犯在肝癌综合诊断与治疗中的临床意义[J]．中华消化外科杂志，2019, 18(4):336-341.

施引文献

资源附件(0)

访问统计